Deborah J. Wexler MD, MScAssociate Professor of Medicine, Harvard Medical School; Associate Clinical Chief of the Diabetes Unit and Clinical Director, Massachusetts General Hospital Diabetes Center, Boston, Massachusetts
Deborah J. Wexler, MD, MSc, is Associate Professor of Medicine at Harvard Medical School, Boston, Massachusetts, the Associate Clinical Chief of the MGH Diabetes Unit, and Clinical Director of the MGH Diabetes Center.
Dr. Wexler’s research focuses on clinical effectiveness in type 2 diabetes. In addition, she served on the American Diabetes Association’s Professional Practice Committee (2014-2016), is on the Editorial Board of Diabetes Care, and is a reviewer for multiple journals.
Dr. Wexler was a co-author of the ADA-EASD Consensus Report on Management of Type 2 Diabetes, 2018 https://care.diabetesjournals.org/content/early/2018/09/27/dci18-0033
Dr. Wexler reports serving on Data Monitoring Committees for trials of oral semaglutide sponsored by Novo Nordisk.
Recent Contributions to PracticeUpdate:
- 2020 Top Stories in Diabetes: The DAPA-CKD Trial
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
- 2019 Top Stories in Diabetes: The CREDENCE Trial
- Cannabis Use Is Associated With Increased Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes
- Even Moderate Weight Loss After Diabetes Diagnosis Improves Long-Term Cardiovascular Risk
- Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
- ADA Scientific Sessions 2019: Recommendations From Dr. Deborah Wexler
- Morbidity and Mortality After Lifestyle Intervention for People With Impaired Glucose Tolerance
- 2018 Top Stories in Diabetes: Canagliflozin and Renal Outcomes in Type 2 Diabetes
- Levels of Adherence Needed to Achieve Significant Weight Loss